54º
    • News
    • Watch Live
    • Michigan COVID
    • Get Caught Up
    • Elections
    • Help Me Hank
    • Health
    • Local News
    • National
    • World
    • Community
    • Investigations
    • Entertainment
    • Environment
    • Politics
    • Flashpoint
    • Trust Index
    • Solutionaries
    • Meet The Team
    • Sports
    • Lions
    • Lions Stats
    • Tigers
    • Tigers Stats
    • Red Wings
    • Red Wings Stats
    • Pistons
    • Pistons Stats
    • Wolverines
    • Spartans
    • 4Frenzy
    • Bob Krause Golf
    • Features
    • Watch Local 4+
    • Parade
    • Vote 4 The Best
    • Click On Deals
    • Jobs 4 You
    • 4YI
    • All 4 Pets
    • Tech Time
    • Travel
    • Something Good
    • Mental Health Matters
    • StyleWise
    • Money Minute
    • Tasty Tuesday
    • Fitness Friday
    • Brag Book
    • Sunshine Awards
    • In The D
    • Food
    • TV Listings
    • MeTV Detroit
    • Contests
    • Live In The D
    • Dine In The D
    • Click On Deals
    • What's The Buzz
    • Uniquely Detroit
    • Events Live Guide
    • Ann Arbor
    • Headlines
    • Topics
    • Sports
    • Events
    • Ann Arbor Weather
    • Get Involved
    • Weather
    • Weather Center
    • Weather News
    • Alerts
    • StormPins
    • School Closings
    • Forecasting Change
    • 4ZONE - Metro
    • 4ZONE - North
    • 4ZONE - South
    • 4ZONE - West
    • Traffic
    • Road Construction Updates
    • Live Traffic Map
    • Newsletters
    • Contact Us
  • News
  • Sports
  • Features
  • Live In The D
  • Ann Arbor
  • Weather
  • Traffic
  • Newsletters
  • Contact Us
ClickOnDetroit.com
  • News
  • Sports
  • Features
  • Live In The D
  • Ann Arbor
  • Weather
  • Traffic
  • Newsletters
  • Contact Us
Ad

MERCK


Merck sold $3.2 billion of its Covid oral antiviral treatment, driving first-quarter revenue growth

Merck soundly beat Wall Street estimates for its top and bottom lines, reporting earnings of $2.14 per share on $15.9 billion in revenue.

cnbc.com

EXPLAINER: COVID-19 pills must be taken within 5 days

COVID-19 patients have two treatment options that can be taken at home.

Merck's Keytruda reduced risk of disease recurrence or death in early lung cancer patients by 24%

Merck plans to submit the data on early stage lung cancer to the FDA as soon as possible.

cnbc.com

EXPLAINER: Why Pfizer needs time to make COVID-19 treatment

Pfizer’s new COVID-19 treatment came with a catch when it debuted late last year: It can take months to make the tablets.

Merck expects to sell $5 billion to $6 billion of its new Covid treatment pill in 2022

CEO Rob Davis said Merck is on track to fulfill its commitment in the coming days of delivering 3.1 million courses of its Covid treatment pill to the U.S.

cnbc.com

Who is eligible for new antiviral pills, monoclonal antibodies to treat COVID-19?

For COVID-19 therapies, there is limited supply and high demand, meaning it is difficult for most to access new antiviral pills and monoclonal antibodies. The window is a bit longer, 5 to 10 days, for monoclonal antibodies, more readily available. RELATED: Monoclonal antibodies even more limited as omicron overtakes delta; new antiviral pills also scarceThe antibodies, said to reduce chances of hospitalization and death by 70%, should be considered for patients who are in eligible lower risk tiers. There are three available monoclonal antibodies. “Our patients shouldn’t be counting on monoclonal antibodies,” Dr. Gordana Simeunovic, an infectious disease physician and head of Grand Rapids-based Spectrum Health’s mAbs program, said earlier this month.

mlive.com

More than 2 dozen drugmakers to make Merck’s COVID-19 pill

A U.N.-backed group says it has signed agreements with more than two dozen generic drug makers to produce versions of Merck’s coronavirus pill to supply 105 developing countries.

In the wake of unequal vaccine rollouts, countries face a ‘Wild West’ scramble for covid pills

Experts fear that despite generic versions of the drug already available, pills produced by Pfizer and Merck could end up largely bought up by rich countries.

washingtonpost.com

COVID-19 Pill Rollout Stymied By Shortages As Omicron Rages

The pills are being carefully rationed, reserved for the highest-risk patients.

www1.newsy.com
Ad

COVID-19 Pill Rollout Stymied By Shortages As Omicron Rages

The pills are being carefully rationed, reserved for the highest-risk patients.

newsy.com

COVID-19 pill rollout stymied by shortages as omicron rages

Two brand-new COVID-19 pills that were supposed to be an important weapon against the pandemic in the U.S. are in short supply and have played little role in the fight against the omicron wave of infections.

Michigan receives first shipment of COVID pill treatment for limited use

Michigan health officials say the state has received its first shipment of newly authorized COVID-19 pill treatments, but it’ll only be prescribed in certain situations due to limited supply.

EXPLAINER: New easy-to-use COVID-19 pills come with a catch

Newly infected COVID-19 patients have two new treatment options that can be taken at home.

EXPLAINER: New easy-to-use COVID-19 pills come with a catch

The challenge is getting tested, getting a prescription and starting the pills in a short window. U.S. regulators authorized Pfizer's pill, Paxlovid, and Merck’s molnupiravir last week. In high-risk patients, both were shown to reduce the chances of hospitalization or death from COVID-19, although Pfizer's was much more effective.

news.yahoo.com

Where four-legged robot dogs are finding work in a tight labor market

These robotic dogs are mobility platforms that can be equipped with different payloads depending on the type of information that companies want to gather.

cnbc.com

FDA authorizes emergency use of two COVID-19 pills to treat mild to moderate COVID-19

The U.S. Food and Drug Administration on Wednesday and Thursday approved for emergency use two pills to treat mild to moderate COVID-19 when there is a high risk the disease could progress, necessitating hospitalization or causing death. They were unvaccinated adults with mild or moderate COVID-19 and chronic medical conditions or an increased risk of SARS-CoV-2 infection. RELATED: FDA advisors narrowly recommend Merck’s COVID-19 pillWith Paxlovid, patients could experience impaired sense of taste, diarrhea, high blood pressure and muscle aches, the FDA says. RELATED: Demand for monoclonal antibodies to treat COVID-19 is high, supply is low — and omicron is comingThe situation could be worsened by the rise of omicron. Michigan diner owner who defied state shutdown dies of COVID-19Feds sending emergency medical team to Mercy Health Muskegon during COVID-19 surge

mlive.com

U.S. authorizes Merck pill to fight COVID-19

Just one day after authorizing Pfizer's Paxlovid pill for at-home use, health regulators have authorized a second pill to combat COVID-19.

arabamericannews.com

U.S. Adds Merck Pill As 2nd Easy-To-Use Drug Against COVID-19

The Food and Drug Administration authorization comes one day after the agency cleared a competing drug from Pfizer.

newsy.com
Ad

U.S. Adds Merck Pill As 2nd Easy-To-Use Drug Against COVID-19

The Food and Drug Administration authorization comes one day after the agency cleared a competing drug from Pfizer.

www1.newsy.com

FDA authorizes Pfizer's Covid treatment pill, the first oral antiviral drug cleared during the pandemic

The Food and Drug Administration has granted emergency authorization to Pfizer's Covid treatment pill, a major milestone that promises to revolutionize the fight against the virus. Pfizer's pill is the first oral antiviral drugs authorized by the FDA that are specifically designed to fight Covid. The U.S. has purchased 10 million courses of Pfizer's treatment, Paxlovid, in a $5 billion deal. Pfizer's treatment is administered in two 150 milligram tablets along with a 100 milligram tablet of an HIV drug, ritonavir, twice daily. Merck's 800 milligram pill is taken every 12 hours for five days after symptom onset.

cnbc.com

FDA authorizes 1st antiviral pill for COVID

In a highly anticipated decision, the Food and Drug Administration authorized Pfizer's Paxlovid as the first antiviral pill to treat COVID-19 at home.

npr.org

Pfizer says experimental COVID pill PAXLOVID reduces risk of hospitalization, death

Pfizer said its experimental COVID pill reduces the risk of hospitalization or death by 89%.

Pfizer Confirms COVID Pill's Results, Potency Against Omicron

The company announced that laboratory testing shows the drug retains its potency against the Omicron variant.

newsy.com

Pfizer confirms COVID pill's results, potency versus omicron

Pfizer says that its experimental COVID-19 pill appears effective against the omicron variant.

How Pfizer developed a COVID pill in record time

Pfizer researchers looking for a drug to treat SARS found clues that gave the company a head start in its quest for a pill to treat COVID-19, including the omicron variant.

npr.org

Risk vs. reward: US panel narrowly recommends Merck’s COVID pill

An anti-COVID pill made by drugmaker Merck has been under review by officials, and on Wednesday its fate rested in the hands of the FDA.

New COVID treatment pill closer to being available

A new antiviral coronavirus treatment pill is close to being made available to patients. The pill works to reduce the progression of severe symptoms and hospitalizations.

Ad

FDA advisers endorse Merck's COVID antiviral drug in narrow vote

The vote paves the way for the agency to authorize molnupiravir for emergency use in American adults.

cbsnews.com

FDA Panel Backs First-Of-A-Kind COVID-19 Pill From Merck

An FDA advisory panel has backed Merck's experimental antiviral medication to treat COVID.

newsy.com

FDA advisors narrowly recommend Merck’s COVID-19 pill for authorization

Thirteen members voted in favor of recommending authorization, while the remaining 10 members voted against authorization. It was developed by New Jersey-based pharmaceutical company Merck and Ridgeback Biotherapeutics, and was used on more than 700 patients during clinical trials. Use of molnupiravir in clinical trials reduced the risk of hospitalization or death from COVID-19 by 30%, according to the company’s clinical trial data. Merck has requested emergency use authorization for the pill, which would be made available via prescription for high-risk patients with mild-to-moderate cases of COVID-19 during the first five days of illness. If granted emergency authorization, molnupiravir would be the first oral antiviral medicine available for COVID-19 in the U.S.

mlive.com

FDA advisers endorse Merck's COVID antiviral drug in narrow vote

The vote paves the way for the agency to authorize molnupiravir for emergency use in American adults.

cbsnews.com

FDA advisory panel narrowly endorses Merck's oral Covid treatment pill, despite reduced efficacy and safety questions

A Food and Drug Administration advisory panel on Tuesday narrowly endorsed the use of Merck and Ridgeback Biotherapeutics' oral Covid treatment pill, despite questions about the drug's effectiveness, safety and whether it would help the virus mutate into even more dangerous variants. The drug needs final approval from the FDA and Centers for Disease Control and Prevention before it's available to the public. Molnupiravir works by prompting the virus that causes Covid to mutate and produce errors inhibiting its ability to replicate and spread. Hildreth told Kartsonis that it is incumbent on Merck to estimate the likelihood of escape mutants. Pfizer is similarly seeking approval for its own oral Covid treatment pill that it said was 89% effective in preventing hospitalization and death when administered with a popular HIV drug.

cnbc.com

FDA Reviewing Merck's COVID Pill For Emergency Authorization

The pharmaceutical company is seeking emergency authorization for the pill to be used in high-risk patients who could become severely ill.

newsy.com

Merck’s COVID-19 pill narrowly wins FDA panel’s support

In a closely watched review, an FDA panel voted 13 to 10 to recommend authorization of Merck's COVID-19 pill, though with many caveats.

latimes.com

FDA Says Merck COVID Pill Effective, Experts To Review Safety

The regulator said the experimental antiviral pill is effective against the virus but identified several potential risks, including birth defects.

newsy.com

FDA Says Merck COVID Pill Effective, Experts To Review Safety

The regulator said the experimental antiviral pill is effective against the virus but identified several potential risks, including birth defects.

www1.newsy.com
Ad

FDA says Merck's COVID-19 pill is effective and the agency will seek advice on risks during pregnancy

Federal health regulators said they will seek input from outside experts on risks of birth defects and other potential problems during pregnancy.

cbsnews.com

Stocks making the biggest moves before the bell: Delta, Moderna, Zoom Video, Microsoft & more

These are the stocks posting the largest moves in the premarket.

cnbc.com

EU says Merck's COVID pill can be taken in emergencies

The European Medicines Agency has issued emergency use advice for using Merck’s COVID-19 pill, even though the oral medicine has not yet been authorized.

Bill Gates: These 2 strategies could control the Covid pandemic by summer

Bill Gates says vaccines and antiviral drugs could get the Covid pandemic to a manageable point by summer 2022. Here's how.

cnbc.com

These 2 Covid pills could be available soon — and they might help end the pandemic. Here's how

Antiviral pills that treat Covid are on the way to approval. Here's what you need to know about molnupiravir from Merck and Paxlovid from Pfizer, two promising medications.

cnbc.com

Pfizer Asks U.S. Officials To OK Promising COVID-19 Pill

It is one of a handful of pills that have recently been shown to significantly cut hospitalizations and deaths among people infected with COVID-19.

newsy.com

Pfizer asks FDA to grant emergency authorization for its COVID-19 pill

Drugmaker is asking regulators to authorize its experimental coronavirus pill for people with mild to moderate infections.

cbsnews.com

Pfizer asks US officials to OK promising COVID-19 pill

Pfizer is seeking U.S. authorization of its experimental COVID-19 treatment pill.

When will Americans be able to get a COVID-19 antiviral pill?

Merck and Pfizer are pursuing emergency authorization for pills to treat COVID-19.

cbsnews.com
Ad

Fauci, Walensky Tackle Questions On COVID At Senate Hearing

Top health officials sounded off before a key Senate committee about what happens next in the fight against the coronavirus.

newsy.com

Pfizer CEO says Covid vaccines, boosters needed to break cycle of virus even with effective pills

Booster doses as well as Pfizer's new Covid pills could be a powerful combo in the fight against Covid.

cnbc.com

Pfizer says its COVID-19 pill cuts disease's worst risks by 89%

Based on the strength of the trial's results, Pfizer says it will ask the FDA for emergency use authorization rather than enroll more people for clinical trials.

npr.org

Pfizer COVID-19 Pill Reduced Deaths, Hospitalizations by 89%

The drugmaker says it will ask for FDA authorization as soon as possible.

newsy.com

New antiviral pill for COVID cut hospital and death risk by 89%, Pfizer says

Pfizer said it will ask the FDA and international regulators to authorize its pill as soon as possible.

cbsnews.com

Pfizer says effectiveness of COVID antiviral pill is 'beyond our wildest dreams'

Pfizer says effectiveness of COVID antiviral pill is 'beyond our wildest dreams'

news.yahoo.com

Pfizer says COVID-19 pill cut hospital, death risk by 90%

Pfizer says its experimental pill for COVID-19 cut rates of hospitalization and death by nearly 90% among patients with mild-to-moderate infections.

Pfizer says its Covid pill with HIV drug cuts the risk of hospitalization or death by 89%

Pfizer said its Covid-19 pill, used with an HIV drug, cut the risk of hospitalization or death by 89% in high-risk adults who've been exposed to the virus.

cnbc.com

Covid Drugs Will Change the Way We Live With the Virus

Good news about at-home Covid treatments from Merck and Pfizer offer some hope as infections surge again.

washingtonpost.com
Ad

UK Authorizes Merck Antiviral Pill, 1st Shown To Treat COVID

Patients 18 and older with mild-to-moderate COVID-19 would take four pills of the drug, known as molnupiravir, twice a day for five days.

www1.newsy.com

UK Authorizes Merck Antiviral Pill, 1st Shown To Treat COVID

Patients 18 and older with mild-to-moderate COVID-19 would take four pills of the drug, known as molnupiravir, twice a day for five days.

newsy.com

Everything You Need to Know About Merck’s Game-Changing Covid Pill

Molnupiravir, an antiviral pill being developed by Merck & Co., has been touted as a potential game changer in the fight against Covid-19. The experimental medication was shown to reduce the risk of hospitalization or death by about half in a late-stage study of adults with mild-to-moderate cases. The promise of a drug that patients can easily get and take at home has prompted some governments to order supplies even before most regulators have decided whether to approve its use.

washingtonpost.com

Why a New Pill to Treat Covid Could Be a Game Changer: QuickTake

Molnupiravir, an antiviral pill being developed by Merck & Co., has been touted as a potential game changer in the fight against Covid-19. The experimental medication was shown to reduce the risk of hospitalization or death by about half in a late-stage study of adults with mild-to-moderate cases. The promise of a drug that patients can easily get and take at home has prompted some governments to order supplies even before most regulators have decided whether to approve its use.

washingtonpost.com

Merck’s Approved Covid Drug Fills In Where Vaccines Can’t

The U.K. is the first country to approve an at-home treatment for the virus. The decision couldn’t be timelier.

washingtonpost.com

U.K. Approves Merck Antiviral Pill To Treat COVID-19

The pill is licensed for adults 18 or older who have tested positive for the virus and have at least one health risk factor.

newsy.com

U.K. Approves Merck Antiviral Pill To Treat COVID-19

The pill is licensed for adults 18 or older who have tested positive for the virus and have at least one health risk factor.

www1.newsy.com

The U.K. approves Merck's COVID-19 antiviral pill, calling it a world first

"The U.K. is now the first country in the world to approve an antiviral that can be taken at home for COVID-19," Health and Social Care Secretary Sajid Javid said.

npr.org

The U.K. approves Merck's COVID-19 antiviral pill, calling it a world first

"The U.K. is now the first country in the world to approve an antiviral that can be taken at home for COVID-19," Health and Social Care Secretary Sajid Javid said.

npr.org
Ad

Cheap antidepressant shows promise treating early COVID-19

A new study found a cheap antidepressant reduced the need for hospitalization among high-risk adults with COVID-19.

FDA unlikely to rule on Merck's COVID pill before December

The U.S. Food and Drug Administration will ask its outside experts to review Merck's pill to treat COVID-19 at a meeting in late November.

Merck asks FDA for emergency use authorization for COVID-19 pill

Drugmaker Merck asked U.S. regulators Monday to authorize its pill for treating COVID-19 in what would add an entirely new and easy-to-use weapon to the world’s arsenal against the pandemic.

Morning Briefing Oct. 11, 2021: Beaumont Health offers signing bonus amid critical nurse shortage, drugmaker Merck asks FDA to authorize anti-COVID pill

Here are this morning's top stories.

Morning Briefing Oct. 2, 2021: Construction workers find human remains under sidewalk in Detroit, why some Michigan counties are rescinding school mask mandates, Merck COVID pill a potential game chan

Here are this morning's top stories.

COVID antiviral pill reduces hospitalizations, deaths by half, drug maker says

There may soon be another weapon in the battle against COVID-19.

Morning Briefing Oct. 1, 2021: Madison Heights pharmacy busted for selling prescription drugs without prescriptions, some Michigan counties rescind school mask mandates

Here are this morning's top stories.

The Latest: 92% of Denver’s municipal employees vaccinated

At least 92% of Denver’s municipal employees were vaccinated against COVID-19 Friday, a day after the city’s vaccine mandate took effect in a bid to slow the spread of the virus during the fall and winter, according to a review of city compliance data.

Stocks rebound but still close out worst week since winter

Stocks rebounded on Wall Street Friday but still ended with their worst weekly decline since February.

Ad

Ann Arbor’s Strata Oncology secures $90 million in recent funding round

Strata Oncology in Ann Arbor raised $90 million in a Series C financing round.

New Merck pneumonia vaccine OK'd in US weeks after Pfizer's

U.S. regulators have approved a new pneumonia vaccine from Merck, more than a month after OK'ing an improved version of rival Pfizer’s shot.

US cervical cancers fall but other sex-related cancers rise

A new study shows screening and the HPV vaccine have led to drops in cervical cancers over the last two decades in the U.S. But those gains are offset by a rise in other tumors caused by the virus.

President Biden speaks on anniversary of COVID shutdown

(AP Photo/Andrew Harnik)President Joe Biden delivered his first prime-time speech since taking office. Related: Congress OKs $1.9T virus relief bill in win for Biden, DemsEarlier Thursday, Biden signed a landmark $1.9 trillion COVID-19 relief bill. “This historic legislation is about rebuilding the backbone of this country,” Biden said as he signed the bill in the Oval Office. Biden originally planned to sign the bill on Friday, but it arrived at the White House more quickly than anticipated. Ad“We want to move as fast as possible,” tweeted White House chief of staff Ron Klain.

Watch live: President Biden addresses nation on anniversary of COVID shutdown

(AP Photo/Andrew Harnik)President Joe Biden is set to deliver his first prime-time address since taking office. Watch live at 8 p.m. Thursday:Related: Congress OKs $1.9T virus relief bill in win for Biden, DemsEarlier Thursday, Biden signed a landmark $1.9 trillion COVID-19 relief bill. “This historic legislation is about rebuilding the backbone of this country,” Biden said as he signed the bill in the Oval Office. Biden originally planned to sign the bill on Friday, but it arrived at the White House more quickly than anticipated. Ad“We want to move as fast as possible,” tweeted White House chief of staff Ron Klain.

Live stream: President Biden addresses nation on anniversary of COVID shutdown

(AP Photo/Andrew Harnik)President Joe Biden delivered his first prime-time address since taking office. This live stream has endedRelated: Congress OKs $1.9T virus relief bill in win for Biden, DemsEarlier Thursday, Biden signed a landmark $1.9 trillion COVID-19 relief bill. “This historic legislation is about rebuilding the backbone of this country,” Biden said as he signed the bill in the Oval Office. Biden originally planned to sign the bill on Friday, but it arrived at the White House more quickly than anticipated. Ad“We want to move as fast as possible,” tweeted White House chief of staff Ron Klain.

Biden holds event with Johnson & Johnson and Merck CEOs

FILE - In this March 5, 2021, file photo, President Joe Biden participates in a roundtable discussion on a coronavirus relief package in the State Dining Room of the White House in Washington. (AP Photo/Patrick Semansky, File)President Biden hosted an event with the CEOs of Johnson & Johnson and Merck Wednesday afternoon at the White House. Merck had previously been working on two of its vaccine candidates but stopped that work after early clinical trial data showed a poor immune response. The J&J vaccine can be stored in a normal refrigerator unlike the Pfizer and Moderna vaccines -- it’s not a mRNA vaccine. Johnson & Johnson CEO Alex Gorsky is a native Michigander.

Merck to help manufacture Johnson & Johnson COVID-19 vaccine

DETROIT – President Joe Biden announced that pharmaceutical giant Merck & Co. will help manufacture Johnson & Johnson’s COVID-19 vaccine. The arrangement comes after officials found out that Johnson & Johnson had fallen behind on production. Johnson & Johnson has pledged 16 million additional doses by the end of the month. READ: Michigan loosens COVID restrictions on restaurants -- here are all the detailsMichigan is also playing a role in the Johnson & Johnson vaccine. READ: Grand Rapids-based Grand River Aseptic to help manufacture J&J vaccineAdQuestions about coronavirus?

The Latest: Ontario seniors won't get AstraZeneca vaccine

The administration is invoking the Defense Production Act, a wartime measure that gives the federal government authority to direct private companies to meet the needs of the national defense, to equip two Merck facilities to produce the Johnson & Johnson vaccine. AdBiden said Johnson & Johnson will operate 24/7 to produce the vaccine. Tom Wolf said Tuesday that teachers will receive doses of the newly approved one-shot Johnson & Johnson vaccine, under a plan his administration will release. AdHe gave few details, but said he and a bipartisan legislative task force agreed that the Johnson & Johnson vaccine should be set aside for teachers and then other workers considered to be essential, but who are not included in the first vaccination phase. States are receiving 2.8 million doses of the newly approved Johnson & Johnson vaccine this week.

Longtime Merck CEO, minority advocate Ken Frazier to retire

(AP Photo/Seth Wenig, File)KENILWORTH – Longtime Merck executive Ken Frazier, whose leadership helped bring the drugmaker one of the most lucrative medicines in history and who is one of the few remaining Black CEOs of a major corporation, is retiring. Frazier, Merck’s CEO since early 2011 and an advocate for minority advancement who took on then-President Trump’s tacit support of white supremacists, will retire on June 30. He is one of the few Black CEOs at the head of a Fortune 500 company. At Merck, Frazier clashed with then-President Donald Trump over his refusal to condemn violence by the white supremacists who marched in Charlottesville, Virginia, in 2017. Share prices have more than doubled, and revenue has nearly doubled, under Frazier as CEO.

Merck ends development of two potential COVID-19 vaccines

The drugmaker will stop developing two potential COVID-19 vaccines after seeing poor results in early-stage studies. (AP Photo/Seth Wenig, File)Merck is giving up on two potential COVID-19 vaccines following poor results in early-stage studies. The company said its potential vaccines were well tolerated by patients, but they generated an inferior immune system response compared with other vaccines. Merck was developing one of the potential vaccines with France’s Pasteur Institute based on an existing measles vaccine. Five potential vaccines have reached late-stage testing in the United States, the final phase before a drugmaker seeks approval from regulators.

The Latest: Texas COVID-19 hospitalizations continue to fall

State health officials Monday reported fewer than 13,000 people were being treated for the virus in Texas hospitals, marking the seventh consecutive day of declining patient loads. Some hospitals and clinics have reported having to cancel immunization appointments because they didn’t have enough vaccine doses to distribute. A little more than half of Ochsner employees have yet to get the vaccine, officials said at a news conference Monday. Tessa Walker Linderman, co-lead of Alaska’s COVID-19 Vaccine Task Force, told reporters the state expects to learn soon what its vaccine allocation will be for February. Health officials are also worried about variants that were first reported in the United Kingdom and South Africa.

Merck sales soar but 3Q profit dips on higher spending

KENILWORTH, NJ Big jumps in sales of Merck's top two blockbuster drugs drove revenue up 15%, but higher spending across the board pushed profits down 3% in the third quarter. The quarter was dominated again by advanced cancer drug Keytruda, with sales soaring 62% to $3.07 billion, more than a quarter of Merck's $11.1 billion in revenue from prescription medicines. The maker of Januvia Type 2 diabetes pills and vaccines on Tuesday reported total revenue of $12.4 billion, including $1.12 billion in sales of veterinary medicines. Merck narrowed and raised its per-share 2019 profit forecast to between $5.12 and $5.17, up from its July forecast of $3.78 to $3.88. It also narrowed and raised its full-year forecast for sales to a range of between $46.5 billion and $47 billion, up from between $45.2 billion and $46.2 billion.

  • TV Listings
  • Contests and Rules
  • Email Newsletters
  • RSS Feeds
  • Closed Captioning
  • Contact Us
  • Careers at WDIV
  • Terms of Use
  • Privacy Policy
  • Public File
  • FCC Applications
  • Do Not Sell My Info
Follow Us
facebook
twitter
instagram
snapchat
rss
Get Results with Omne
Omne Results Logo

If you need help with the Public File, call (313) 222-0566.


Graham Media Group LogoGraham Digital Logo

Copyright © 2022 ClickOnDetroit.com is managed by Graham Digital and pubished by Graham Media Group, a division of Graham Holdings.